JanOne Advances Toward Initiation of Phase 2b Peripheral Artery Disease (PAD) Trial for Lead Product Candidate JAN101
JanOne Inc. (Nasdaq: JAN) has successfully completed the CGMP production of the first batch of JAN101, a sustained-release medication aimed at treating Peripheral Artery Disease (PAD). The initial batch produced contains approximately 200,000 tablets and placebos. This marks a significant milestone as JanOne prepares for its Phase 2b trial, focusing on improving vascular function and alleviating neuropathic pain. The FDA-regulated CGMP compliance indicates JanOne's commitment to quality manufacturing. The company also explores the use of JAN101 for other vascular complications.
- Successful completion of CGMP production of JAN101.
- Approximately 200,000 sustained-release tablets produced.
- Preparation for Phase 2b trial indicates progress in drug development.
- Potential to transform treatment for PAD and other vascular conditions.
- None.
LAS VEGAS, June 8, 2021 /PRNewswire/ -- JanOne Inc. (Nasdaq: JAN), a company focused on developing treatments for conditions that cause severe pain and drugs with non-addictive, pain-relieving properties, today announced the successful completion of Current Good Manufacturing Practices (CGMP) production of the first batch of JAN101 for its upcoming Phase 2b trial for treating Peripheral Artery Disease (PAD).
The initial batch, produced by manufacturing partner CoreRX, contains approximately 200,000 sustained release tablets and matching placebos of JAN101, a patented sustained-release form of sodium nitrite aimed at improving vascular function and reducing neuropathic pain and other conditions resulting from poor blood flow. JAN101 is highly selective, acting only in damaged tissue.
"Completion of the CGMP batch is an exciting achievement as we advance toward our planned Phase 2b PAD trial for JAN101," said Tony Isaac, President and Chief Executive Officer of JanOne. "With CGMP compliance, we've proven our ability to economically scale-up production of JAN101 while preserving the product's identity, strength, quality, and purity. We are now focused on bottling and labeling JAN101 for distribution to clinical test sites and engaging a contract research organization (CRO) to manage our Phase 2b trial, including the recruitment of subjects."
Commenting on potential indications for JAN101, Isaac added, "Therapeutic options available for patients with PAD are extremely limited, and we believe our solution has the potential to transform the standard of care to an easy twice-a-day pill that substantially improves moderate to severe PAD and minimizes pain associated with the disease. We are also exploring the potential of JAN101 as a treatment for other conditions involving vascular complications, including chronic kidney disease, and, with our initial batch, we now have additional product available for collaborations with independent investigators on this and additional indications."
The U.S. Food and Drug Administration (FDA) regulates the quality of pharmaceuticals through its main standard CGMP. Completion of CGMP production signifies that JanOne is fully compliant with the FDA's formal regulations regarding the design, monitoring, control, and maintenance of manufacturing processes and facilities for JAN101.
About JanOne
JanOne (Nasdaq: JAN) is focused on developing treatments for diseases that cause severe pain. By alleviating pain at the source, JanOne aims to reduce the need for opioid prescriptions to treat disease associated pain that can lead to opioid abuse. The company is also exploring solutions for non-addictive pain medications. Its lead candidate, JAN101, is for potentially treating peripheral artery disease ("PAD"), a condition that affects over 8.5 million Americans. JAN101 demonstrated positive results in a Phase 2a clinical trial, and Phase 2b trials are expected to begin in the near future. JanOne is dedicated to funding resources toward innovation, technology, and education for PAD, associated vascular conditions, and neuropathic pain. For more information, visit www.janone.com.
Forward-Looking and Cautionary Statements
This press release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. In accordance with the safe harbor provisions of this Act, statements contained herein that look forward in time that include everything other than historical information, including statements relating to the commencement of the upcoming Phase 2b trials, whether JAN101 can treat other conditions involving vascular complications, including chronic kidney disease. These forward-looking statements can be identified by terminology such as "will," "aims," "upcoming," "may," "expects," "expected," "potential," "anticipates," "future," "intends," "plans," "believes," "estimates" and similar statements. JanOne may also make written or oral forward-looking statements in its periodic reports to the U.S. Securities and Exchange Commission (the "SEC") on Forms 10-K and 10-Q, Current Reports on Form 8-K, in its annual report to stockholders, in press releases, and other written materials and in oral statements made by its officers, directors or employees to third parties. There can be no assurance that such statements will prove to be accurate and there are a number of important factors that could cause actual results to differ materially from those expressed in any forward-looking statements made by the company, including, but not limited to, plans and objectives of management for future operations or products, the market acceptance or future success of our products, and our future financial performance. The company cautions that these forward-looking statements are further qualified by other factors including, but not limited to, those set forth in the company's Annual Report on Form 10-K for the fiscal year ended January 2, 2021 and other SEC filings (available at http://www.sec.gov). JanOne undertakes no obligation to publicly update or revise any statements in this release, whether as a result of new information, future events, or otherwise.
Investor Relations & Media Contact
IR@Janone.com
1 (800) 400-2247
View original content to download multimedia:http://www.prnewswire.com/news-releases/janone-advances-toward-initiation-of-phase-2b-peripheral-artery-disease-pad-trial-for-lead-product-candidate-jan101-301307929.html
SOURCE JanOne Inc.
FAQ
What is the purpose of JAN101?
When will the Phase 2b trial for JAN101 begin?
How many tablets are in the initial batch of JAN101?
What does CGMP compliance signify for JanOne?
What other conditions could JAN101 potentially treat?
